Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6IMI4
UPID:
ST6B1_HUMAN
Alternative names:
Thyroxine sulfotransferase
Alternative UPACC:
Q6IMI4; B2RTS7
Background:
Sulfotransferase 6B1, also known as Thyroxine sulfotransferase, plays a pivotal role in the metabolism of thyroxine. It functions by utilizing 3'-phospho-5'-adenylyl sulfate (PAPS) as a sulfonate donor to catalyze the sulfate conjugation of thyroxine. This process is crucial for regulating the bioavailability and activity of thyroxine, a hormone essential for normal metabolism, growth, and development.
Therapeutic significance:
Understanding the role of Sulfotransferase 6B1 could open doors to potential therapeutic strategies. Its involvement in thyroxine metabolism suggests that modulation of its activity could offer new avenues for managing conditions related to thyroid hormone imbalance.